Royalty Pharma plc (NASDAQ: RPRX) is a top high-margin pharma stock to buy, with Morgan Stanley raising its price target to $54 and maintaining an Overweight rating. The company’s cash flow durability and ability to navigate industry challenges impressed analysts.

Despite struggles in the pharmaceutical and biotech sectors, Royalty Pharma stands out with its unique business model of acquiring royalty streams from established and emerging therapies. Revenue from blockbuster drugs like Tysabri and Imbruvica has provided a stable earnings profile, appealing to investors seeking income and resilience.

Royalty Pharma remains well-positioned in a volatile sector, offering defensive qualities for investors. While RPRX presents potential, other AI stocks may offer greater upside potential with less downside risk in the current economic environment. Investors can explore this opportunity further in a free report on the best short-term AI stock.

For more insights on healthcare AI stocks and industrial automation stocks, investors can explore the top picks according to hedge funds. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating